These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 8833961)

  • 41. Impurities in Oligonucleotide Drug Substances and Drug Products.
    Capaldi D; Teasdale A; Henry S; Akhtar N; den Besten C; Gao-Sheridan S; Kretschmer M; Sharpe N; Andrews B; Burm B; Foy J
    Nucleic Acid Ther; 2017 Dec; 27(6):309-322. PubMed ID: 29125795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analytical methods for drugs in the next decade.
    Zarembo JE
    J Assoc Off Anal Chem; 1982 May; 65(3):542-50. PubMed ID: 7096237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The central role of chemistry in 'quality by design' approaches to drug development.
    Grewal NK; Leadbeater NE
    Future Med Chem; 2012 Sep; 4(14):1799-810. PubMed ID: 23043477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. International Conference on Harmonisation; final recommendations on the revision of the permitted daily exposures for two solvents, n-methylpyrrolidone and tetrahydrofuran, according to the maintenance procedures for the guidance Q3C Impurities: Residual Solvents; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Nov; 68(219):64352-3. PubMed ID: 14619948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. International Conference on Harmonisation: guidance on Q1D bracketing and matrixing designs for stability testing of new drug substances and products; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jan; 68(11):2339-40. PubMed ID: 12532979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and validation of a liquid chromatographic method for determination of related-substances of mosapride citrate in bulk drugs and pharmaceuticals.
    Nageswara Rao R; Nagaraju D; Alvi SN; Bhirud SB
    J Pharm Biomed Anal; 2004 Nov; 36(4):759-67. PubMed ID: 15533668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for use in the International Conference on Harmonisation Regions; Annex 4C on Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15992-3. PubMed ID: 19507323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elemental impurities in pharmaceutical products adding fuel to the fire.
    Maithani M; Raturi R; Sharma P; Gupta V; Bansal P
    Regul Toxicol Pharmacol; 2019 Nov; 108():104435. PubMed ID: 31376414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of various international guidelines for analytical method validation.
    Chandran S; Singh RS
    Pharmazie; 2007 Jan; 62(1):4-14. PubMed ID: 17294806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
    Görög S
    Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmaceutical impurities--a mini-review.
    Roy J
    AAPS PharmSciTech; 2002; 3(2):E6. PubMed ID: 12916943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. On-line H/D exchange LC-MS strategy for structural elucidation of pharmaceutical impurities.
    Liu DQ; Wu L; Sun M; MacGregor PA
    J Pharm Biomed Anal; 2007 Jun; 44(2):320-9. PubMed ID: 17317074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Advances on genotoxic impurities of sulfonate esters in pharmaceuticals].
    Liu X; Li C; Han H; Zhang W; Chen D
    Se Pu; 2018 Oct; 36(10):952-961. PubMed ID: 30378353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analytical profile of moxidectin.
    Awasthi A; Razzak M; Al-Kassas R; Harvey J; Garg S
    Profiles Drug Subst Excip Relat Methodol; 2013; 38():315-66. PubMed ID: 23668407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. International Conference on Harmonisation; guidance on electronic common technical document specification; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Apr; 68(63):16060-1. PubMed ID: 12674113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of LC-MS(n) in conjunction with mechanism-based stress studies in the elucidation of drug impurity structure: rapid identification of a process impurity in betamethasone 17-valerate drug substance.
    Li M; Lin M; Rustum A
    J Pharm Biomed Anal; 2008 Dec; 48(5):1451-6. PubMed ID: 18977106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Materials in Manufacturing and Packaging Systems as Sources of Elemental Impurities in Packaged Drug Products: An Updated Literature Review.
    Jenke D
    PDA J Pharm Sci Technol; 2020; 74(3):324-347. PubMed ID: 31843988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.